Kairos Pharma, LTD. - Form 8-K Summary
Business Context and Reporting Period
Kairos Pharma, LTD. (KAPA), a Delaware corporation and emerging growth company, filed this Current Report on September 23, 2024. The filing discloses the entry into two material definitive agreements on the same date to secure advisory and communications services.
Key Financial Metrics
This filing does not report revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on contractual obligations.
- CEO.CA Agreement Fee: $250,000 for a one-year term.
- Belair Capital Advisors (BCA) Fee: $365,000 for a 12-month term.
- Equity Compensation: 50,000 restricted stock units (RSUs) issued to BCA, vesting after six months.
Material Changes
The material change reported is the execution of new service contracts:
- CEO.CA Technologies Ltd.: Agreement for internet-based financial information and communications services, including strategic news placement, releases, interviews, monthly analytics, and a video launch.
- Belair Capital Advisors Inc.: Strategic advisory agreement covering corporate strategy, market positioning, long-term growth planning, digital marketing, market research, and business development.
Outlook, Risks, and Management Commentary
Management commentary is limited to the description of services intended to support the company's growth and market presence. The agreements include customary representations, warranties, indemnification, and governing law clauses. No specific financial guidance or risk factors beyond standard contractual terms are detailed in this filing.
Investor Verification Checklist
- Verify the total cash outflow commitment of $615,000 ($250,000 + $365,000) against current cash reserves.
- Confirm the dilution impact of the 50,000 RSUs issued to Belair Capital Advisors.
- Review the full text of Exhibits 10.1 and 10.2 for termination clauses and specific performance metrics.
- Assess the strategic fit of CEO.CA's communications services for an early-stage pharmaceutical company.